1. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy.
- Author
-
Kilickap S, Ozturk A, Karadurmus N, Korkmaz T, Yumuk PF, Cicin I, Paydas S, Cilbir E, Sakalar T, Uysal M, Yesil Cinkir H, Uskent N, Demir N, Sakin A, Dursun OU, Aver B, Turhal NS, Keskin S, Tural D, Eralp Y, Bugdayci Basal F, Yasar HA, Sendur MAN, Demirci U, Cubukcu E, Karaagac M, Cakar B, Tatli AM, Yetisyigit T, Urvay S, Gursoy P, Oyan B, Turna ZH, Isikdogan A, Olmez OF, Yazici O, Cabuk D, Seker MM, Unal OU, Meydan N, Okutur SK, Tunali D, and Erman M
- Subjects
- Humans, Male, Female, Retrospective Studies, Middle Aged, Adult, Aged, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors adverse effects, Antineoplastic Agents therapeutic use, Antineoplastic Agents adverse effects, Treatment Outcome, Crizotinib therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung diagnostic imaging, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms drug therapy, Lung Neoplasms diagnostic imaging, Lung Neoplasms pathology, Anaplastic Lymphoma Kinase genetics
- Abstract
To evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+ non-small cell lung cancer patients and crizotinib efficacy in different lines. This national, non-interventional, multicenter, retrospective archive screening study evaluated demographic, clinical, and radiological imaging features, and treatment approaches in patients treated between 2013-2017. Totally 367 patients (54.8% males, median age at diagnosis 54 years) were included. Of them, 45.4% were smokers, and 8.7% had a family history of lung cancer. On radiological findings, 55.9% of the tumors were located peripherally, 7.7% of the patients had cavitary lesions, and 42.9% presented with pleural effusion. Pleural effusion was higher in nonsmokers than in smokers (37.3% vs. 25.3%, P = .018). About 47.4% of cases developed distant metastases during treatment, most frequently to the brain (26.2%). Chemotherapy was the first line treatment in 55.0%. Objective response rate was 61.9% (complete response: 7.6%; partial response: 54.2%). The highest complete and partial response rates were observed in patients who received crizotinib as the 2nd line treatment. The median progression-free survival was 14 months (standard error: 1.4, 95% confidence interval: 11.2-16.8 months). Crizotinib treatment lines yielded similar progression-free survival (P = .078). The most frequent treatment-related adverse event was fatigue (14.7%). Adrenal gland metastasis was significantly higher in males and smokers, and pleural involvement and effusion were significantly higher in nonsmokers-a novel finding that has not been reported previously. The radiological and histological characteristics were consistent with the literature data, but several differences in clinical characteristics might be related to population characteristics., Competing Interests: OUD and BA are the employees of Pfizer Biopharmaceuticals Group, Istanbul, Türkiye. BOU reports research support for clinical trials through institution from Novartis, GSK, Astra Zeneca; honoraria from BMS, Amgen, Novartis, Pfizer, Astra Zeneca, Roche, MSD; support for attending meetings from Roche, Pfizer, Novartis and is on the advisory boards of Takeda, Roche, Astra Zeneca, MSD, Novartis, Amgen, Gilead. ME has support funding for medical writing from Pfizer, provides lectures for Pfizer, Novartis, Roche, Astellas, Janssen, MSD, Gen, Nobel, Deva, Eczacibasi, BMS, Takeda, Astra Zeneca, has support for attending meetings from Roche, has participation on advisory board of Novartis, Pfizer, Roche, Astellas, MSD, Deva, Astra Zeneca. The remaining authors have no conflicts of interest to disclose., (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF